Intravenous Immunoglobulin (IVIg) Market Size, Share, Growth Drivers, Investment Opportunities And Strategies

Intravenous Immunoglobulin (IVIg) Market Overview

A new report published by Market Research Future (MRFR) projects that the global intravenous immunoglobulin (IVIG) market will grow at a steady pace over the next several years. The Intravenous Immunoglobulin (IVIg) Market is projected to surpass a valuation of USD US$ 8300 Mn by the year 2023. IVIg is viewed as a ground-breaking medical technology for managing poor immune system.

Patients with immune deficiency are prone to high infection, poor health and weakness. Immune deficiency hinders the production of antibodies (that help fight infection causing germs). Over the years intravenous immunoglobulin (IVIG) has become the treatment of choice for patients with antibody deficiencies. Haematology, nephrology, dermatology, rheumatology, neurology and immunology are some of clinical specialities that are currently using high amounts of IVIG.

Increased prevalence of immune deficiency is driving the demand for IVIG. The global IVIG market will continue to growth on the back of rising popularity of immunoglobulin replacement therapies, increased R&D efforts, advances in IV technology and rising level of awareness and healthcare expenditure. IVIG is effective and has tremendous application prospects is various fields of medical science.

Global Intravenous Immunoglobulin (IVIg) Market: Segmental Analysis

MRFR’s report include comprehensive segmental analysis of the market based on type and application. By type, the market has been segmented into IgG, IgD, IgA and IgE. The IgA segment is further subsegment into IgA1 and IgA2. By application, the market has been segmented into CIPD, Hypogammaglobulinemia, Immunodeficiency diseases, Multifocal Motor Neuropathy, Primary Humoral Immunodeficiency, Myasthenia Gravis, ITP, Kawasaki disease and others. The CIPD segment is further sub-segmented into Monophasic, Recurrent and Progressive. The Hypogammaglobulinemia segment is further sub-segmented into AGM6, AGM5, AGM4, AGM3, AGM2 and AGM1. The Immunodeficiency diseases segment is further sub-segmented inti X-linked agammaglobulinemia (XLA), severe combined immunodeficiency and common variable immunodeficiency (CVID). The Primary Humoral Immunodeficiency segment is further sub-segmented into Defective phagocytes, T cell deficiencies, B cell (antibody) deficiencies, Combination B and T cell deficiencies, and Complement deficiencies, Unknown (idiopathic).  The Myasthenia Gravis segment is further sub-segmented into generalized myasthenia gravis, Transient neonatal myasthenia gravis, Congenital myasthenia gravis and ocular myasthenia gravis. The Guillain-Barre syndrome segment is further sub-segmented into Acute motor axonal neuropathy (AMAN), Acute inflammatory demyelinating polyradiculoneuropathy (AIDP), acute motor-sensory axonal neuropathy (AMSAN) and Miller Fisher syndrome (MFS). The ITP segment has been sub-segmented into chronic and acute.

Global Intravenous Immunoglobulin (IVIg) Market: Regional Analysis

The market has been covered across regions such as North America, Latin America, Europe, the Middle East & Africa (MEA) and Asia Pacific (APAC) Among these, North America currently accounts for the largest market share. Europe, particularly Western Europe is also projected to remain a highly lucrative market for IVIG. Europe is the second largest market for IVIG and is likely to maintain its position throughout the assessment period. The market in APAC is expected to exhibit a significant growth in the forthcoming years. Advances in healthcare infrastructure and increase healthcare expenditure is supporting the growth of the market in the region. Regions and MEA and LatAm are also expected to witness healthy growth but from a smaller base. Many of the regions are home to large pools of low-income individuals who are unable to afford the expensive healthcare services.

Global Intravenous Immunoglobulin (IVIg) Market: Competitive Landscape

ABEONA THERAPEUTICS (US), BDI Pharma (US), China Biologic Products, Inc. (China), Grifols Inc. (Spain), Octapharma (Switzerland), Baxter (US), CSL Behring (US), Biotest AG.(Germany), Kedrion S.p.A (us) and Shire (Republic of Ireland) are some top notch companies profiled in MRFR;s report.

Obtain Premium Research Report Details @

Industry News

Therapure Biopharma Inc biologic division Evolve Biologics (“Evolve”) has recently provided an update on the progress of its Phase III multicenter clinical trial of PlasmaCap™ IG (Intravenous Immunoglobulin or “IVIG”). PlasmaCap™ IG is a new IVIG replacement therapy yet to be used and is being studied in both pediatric patients and adults with primary immune deficiency disorders (“PIDD”).

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

Create your website with
Get started
%d bloggers like this: